Four ways to reuse a molecule
A comparison of starting materials, experimental settings and the work needed to make a finding travel.
Four kinds of reuse
These compounds make a useful collection because reuse means something different in each case. GHK is a sequence embedded in larger structural proteins. KPV corresponds to part of a hormone. PT-141 is an engineered analogue. NAD+ is continually rebuilt through cellular pathways, and its precursors are studied as supplements.
The untidiness is part of its appeal to me. A molecule's ancestry and the depth of its clinical record answer different questions. The contrast is especially clear between KPV’s mouse experiments and bremelanotide’s Phase 3 human trials.
Origin and experimental setting
| Compound | Existing material or pathway | Setting of the evidence discussed here |
|---|---|---|
| GHK-Cu | GHK sequence in collagen and SPARC, with copper binding | Small human topical studies and laboratory work |
| KPV | The final three amino acids of alpha-MSH | Intestinal cells and mouse colitis; rabbit corneal repair; no published human clinical trial |
| PT-141 | A synthetic cyclic analogue of alpha-MSH | Premenopausal women with HSDD in Phase 3 trials; an approved formulation with a narrow indication |
| NAD+ | Cellular production and salvage of a coenzyme | Human oral-precursor trials and a review finding limited efficacy in ageing |
The table is organised by the sort of biological material being reused. It provides no ranking of treatments or safety. The cell, animal and human settings in the final column are the important differences.
Routes and carriers
In GHK research, moving from a local fragment within tissue to something applied outside the skin introduces a barrier. The topical delivery review spends considerable effort on that barrier. KPV research confronts instability and targeting, using nanoparticles and hydrogels in mice. Each formulation adds experimental conditions that a summary has to retain.
PT-141 makes durability a chemical design problem. Its approved label records pharmacokinetics and safety limits for a particular formulation. NAD+ precursor research has a different challenge: the blood marker moves reliably, while human tissue-level dynamics remain sparsely documented.
Admiration for biological economy leaves me hungry for practical detail. Which form reached which tissue, and what happened there? A beautiful origin story becomes more interesting when an experiment can answer that.
Reading the human results together
Bremelanotide's human trials concern acquired, generalised HSDD in premenopausal women. The hair study discussed under GHK tested a combination topical formulation in men with androgenetic alopecia. The NMN insulin-sensitivity study concerned prediabetic postmenopausal women. These populations and outcomes cannot be merged into a single score for peptide benefit.
KPV remains at the preclinical stage in this collection. KPV's unfinished research story still has human safety and efficacy to establish. The questions page addresses common points of confusion; the reference list contains the full source records.